Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats

被引:6
作者
Konishi, H [1 ]
Sumi, M
Shibata, N
Takada, K
Minouchi, T
Yamaji, A
机构
[1] Shiga Univ Med Sci, Dept Hosp Pharm, Otsu, Shiga 5202192, Japan
[2] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Kyoto 607, Japan
关键词
D O I
10.1211/0022357023114
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined the effects of high-dose methylprednisolone (MP) on the disposition of ciclosporin (CsA) and hepatic microsomal CYP3A activity using rats. Methylprednisolone sodium succinate (IMPS), a prodrug of MP, was intravenously administered as repeated doses (66.3 mg kg(-1)) for 3 days or as a single dose. in MP-treated rats, a significant increase was observed in the total body clearance (CLtot) and elimination rate constant (Ke) of intravenously administered CsA. The enzyme activities of triazolam hydroxylations and erythromycin N-demethylation in hepatic microsomes were also enhanced by about 50% by MP treatment, suggesting that the alteration in the CsA pharmacokinetics was due to significant induction of the hepatic CYP3A responsible for the metabolic conversion of CsA. In contrast, no significant changes in the values of CLtot and Ke were found following a single treatment with MP. On the other hand, MP inhibited the CYP3A-mediated triazolam hydroxylations in a concentration-dependent manner. The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 mum). Although there is a general consideration that MP cannot act as an enzyme inducer at maintenance doses, the present results strongly suggest that high-dose MP is likely to interact pharmacokinetically with CsA by inducing hepatic CYP3A. These results may provide basic explanations for the clinical experience that blood CsA levels are reduced during IMP pulse therapy.
引用
收藏
页码:477 / 483
页数:7
相关论文
共 36 条
[1]   Distribution of cyclosporin in organ transplant recipients [J].
Akhlaghi, F ;
Trull, AK .
CLINICAL PHARMACOKINETICS, 2002, 41 (09) :615-637
[2]   METHYLPREDNISOLONE PHARMACOKINETICS AFTER INTRAVENOUS AND ORAL-ADMINISTRATION [J].
ALHABET, SMH ;
ROGERS, HJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (03) :285-290
[3]  
BRAYMAN KL, 1988, TRANSPLANT P, V20, P553
[4]  
Brunner LJ, 1996, J PHARMACOL EXP THER, V277, P1710
[5]   Clinically significant drug interactions with cyclosporin - An update [J].
Campana, C ;
Regazzi, MB ;
Buggia, I ;
Molinaro, M .
CLINICAL PHARMACOKINETICS, 1996, 30 (02) :141-179
[6]   ALTERNATIVE CYCLOSPORINE METABOLIC PATHWAYS AND TOXICITY [J].
CHRISTIANS, U ;
SEWING, KF .
CLINICAL BIOCHEMISTRY, 1995, 28 (06) :547-559
[7]   Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[8]   6-ALPHA-METHYLPREDNISOLONE AND 6-ALPHA-METHYLPREDNISONE PLASMA-PROTEIN BINDING IN HUMANS AND RABBITS [J].
EBLING, WF ;
MILSAP, RL ;
SZEFLER, SJ ;
JUSKO, WJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (08) :760-763
[9]   CYCLOSPORINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN IMMUNOREGULATORY DISORDERS [J].
FAULDS, D ;
GOA, KL ;
BENFIELD, P .
DRUGS, 1993, 45 (06) :953-1040
[10]  
KAHAN BD, 1989, NEW ENGL J MED, V321, P1725